PERSONAL BIOGRAPHY
NAME:
ADDRESS:
Vincent Pius Alibu
Makerere University
College of Natural Sciences
Department of Biochemistry and Sports Sciences
P.O. BOX 7062
KAMPALA
E-MAIL: palibu@cns.mak.ac.ug or vpalibu@yahoo.com
PUBLICATIONS:
 Kimuda MP, Noyes H, Mulindwa J, Enyaru J, Alibu VP, Sidibe I, Mumba
Ngoyi D, Hertz-Fowler C, MacLeod A, Tastan Bishop Ö, Matovu E;
TrypanoGEN Research Group as members of The H3Africa
Consortium.(2018): No evidence of association between APOL1 kidney
disease risk allelles and African trypanosomiasis in two Ugandan populations.
PLoS Negl Trop Dis.12(2):e0006300.
 Kato CD, Mugasa CM, Nanteza A, Matovu E, Alibu VP. (2017): Relationship
between Trypanosoma brucei rhodesiense genetic diversity and clinical
spectrum among sleeping sickness patients in Uganda. BMC Res Notes. Oct
27;10(1):518. doi: 10.1186/s13104-017-2860-x.
 Lamour SD, Alibu VP, Holmes E, Sternberg JM. (2017): Metabolic profiling of
the central nervous system disease in Trypanosoma brucei rhodesiense
infection. J Infect Dis. Sep 12. doi: 10.1093/infdis/jix466
 Ilboudo H, Noyes H, Mulindwa J, Kimuda MP, Koffi M, Kaboré JW, Ahouty B,
Ngoyi DM, Fataki O, Simo G, Ofon E, Enyaru J, Chisi J, Kamoto K, Simuunza
M, Alibu VP, Lejon V, Jamonneau V, Macleod A, Camara M, Bucheton B,
Hertz-Fowler C, Sidibe I, Matovu E; TrypanoGEN Research Group as
members of The H3Africa Consortium. (2017: Introducing the TrypanoGEN
Biobank: A valuable resource for the elimination of African trypanosomiasis.
PLoS
Negl
Trop
Dis.
2017
Jun
1;11(6):
e0005438.
doi:
10.1371/journal.pntd.0005438. eCollection 2017 Jun.
 Cooper A, Ilboudo H, Alibu VP, Ravel S, Enyaru J, Weir W, Noyes H,
Capewell P, Camara M, Milet J, Jamonneau V, Camara O, Matovu E,
Bucheton B, MacLeod A. (2017): APOL1 Renal risk variants have contrasting
resistance and susceptibility associations with African trypansomiasis. Elife.
2017 May 24;6. pii: e25461. doi: 10.7554/eLife.25461.
 Kato CD, Matovu E, Mugasa CM, Nanteza A, Alibu VP. (2016): The role of
cytokines in the pathogenesis and staging of Trypanosoma brucei
rhodesiense Sleeping sickness. Allergy Asthma Clin Immunol. Jan 22;12:4.
doi: 10.1186/s13223-016-0113-5. Review. PMID:26807135
 Kato CD, Matovu E, Mugasa CM, Nanteza A, Alibu VP (2016): The role of
cytokines in pathogenesis and staging of trypansoma brucei rhodesiense
sleeping sickness. Allergy Asthma Clin Immunol. 12:4. doi: 10.1186/s13223016-0113-5.
 Lamour SD, Gomes-Romero M, Vorkas PA, Alibu VP, Saric J, Holmes E and
Sternberg JM (2015): Discovery of infection associated Metabolic markers in
human African Trypanosomiasis. PLoS Negl Trop Dis. 2015 Oct 27;9(10):
e0004200. doi: 10.1371/journal.pntd.0004200. eCollection 2015 Oct.
 Alibu VP, John, Enyaru JCK, Matovu E, Malele II, John E. Chisi, Mbongo N,
Mansinsa P, Intisar ER, Mohammed Y, Abdelrahman MM, Ochi EB and
Lukaw YS (2015): Molecular xenomonitoring of trypanosomes in tsetse flies.
Jr Parasit and Vector Biol. 7(6):1087-114.
1














Kato CD, Alibu VP, Nanteza A, Mugasa CM, Matovu E. (2015): Interleukin
(IL) -6 and IL-10 are upregulated in late stage Trypanosoma brucei
rhodesiense sleeping sickness. PLoS Negl Trop Dis. 9(6): e0003835
Tindana P, de Vries J, Campbell M, Littler K, Seeley J, Marshall P, Troyer J,
Ogundipe M, Alibu VP, Yakubu A, Parker M; as members of the H3A
Working Group on Ethics. (2015): Community engagement strategies for
genomic studies in Africa: a review of the literature. BMC Med Ethics. 16:24.
BMC Med Ethics. 2015 Apr 12; 16:24.
Kato CD, Nanteza A, Mugasa C, Edyelu A, Matovu E, Alibu VP. (2015):
Clinical profiles and disease outcome and co-morbidities among T. b
rhodesiense sleeping sickness patients in Uganda. PLoS One. 10(2):
e0118370.
Enyaru JCK, Njuguna J, Alibu VP, Matovu E, Malele II, Chisi JE, Mbongo N,
Mansinsa P, Intisar ER, Mohammed Y, Mustafa M, Abdelrahman MM, Ochi E
and Nantulya V (2015): Development and evaluation of lateral flow test for the
detection of trypanosomes in tsetse flies. Jr of Parasit and Vector Biol. 6(12)
181-188.
Namuwulya P, Abernathy E, Bukenya H, Bwogi J, Tushabe P, Birungi M,
Seguya R, Kabaliisa T, Alibu VP, Kayondo JK, Rivailler P, Icenogle J,
Bakamutumaho B. (2014): Phylogenetic analysis of rubella viruses identified
in Uganda, 2003-2012. J Med Virol. 86(12):2107-13.
Kerkhoven EJ, Achcar F, Alibu VP, Burchmore RJ, Gilbert IH, Trybiło M,
Driessen NN, Gilbert D, Breitling R, Bakker BM, Barrett MP. (2013): Handling
uncertainty in dynamic models: the pentose phosphate pathway in
Trypanosoma brucei. PLoS Comput Biol. 9 (12): e1003371.
Malele II, Ouma JO, Enyaru JC, Matovu E, Alibu V, Auma JE, Onyoyo SG,
Bateta R, Changasi RE, Mukiria PW, Ndung'u K, Gitonga PK, Mwaniki LM,
Nyingilili HS, Lyaruu EA, Kapange LA, Kamau PK, Masiga DK. (2013):
Comparative diagnostic and analytical performance of PCR and LAMP-based
trypanosome detection methods estimated using pooled whole tsetse flies
and midguts. Vet Parasitol. (13)00345-2.
Alibu VP, Daunes S, D'Silva C. (2013): N-Benzyloxycarbonyl-S-(2,4dinitrophenyl) glutathione dibutyl diester is inhibitory to melarsoprol resistant
cell lines overexpressing the T. bruceiMRPA transporter. Bioorg Med Chem
Lett. 23(15):4351-3
Stoffel SA; Alibu VP; Herbert J; Ebikeme C; Portais JC; Bringaud F;
Schweingruber, ME and Barrett MP (2011): Transketolase in trypanosome
brucei. Mol Biochem Parasitol. 179(1):1-7
Ruda GF, Wong PE, Alibu VP, Norval S, Read KD, Barrett MP, Gilbert IH
(2010): Aryl Phosphoramidates of 5-Phospho Erythronohydroxamic Acid, A
new class of Potent Trypanocidal Compounds. J. Med. Chem. 53, 6071-6078.
Ruda GF, Campbell G, Alibu VP, Barrett MP, Brenk R and Gilbert IH (2010):
Virtual fragment screening of novel inhibitors of 6-phosphogluconate
dehydrogense. Bioorg Med Chem. 18 (14): 5056-5062.
Naula C, Alibu VP, Burchmore RJ, Brock JM, Veitch NJ, and Barrett MP
(2008): A new erythrose 4-phosphate dehydrogenase coupled assay for
transketolase. J. Biochem Biophys Methods 70(6):1185-7.
Ruda GF, Alibu VP, Mitsos C, Bidet O, Kaiser M, Brun R, Barrett MP and
Gilbert IH (2007): Synthesis and biological evaluation of phosphate prodrugs
of 4-phospho-D-erythronohydroxamic acid, an inhibitor of 6-phosphoglunate
dehydrogenase. ChemMedChem. 2 (8): 1169-1180.
Lanteri C, Mhairi SM, Brock J, Alibu VP, Meshnick S, Tidwell RR, Barrett MP
(2006): Roles for the Trypanosoma brucei P2 transporter in DB75 uptake and
resistance. Mol Pharmacol. 70 (5): 1585-1592
2





Colasante C, Alibu VP, Kirchberger S, Tchaden J, Clayton C and Voncken F.
(2006): Characterisation and developmentally regulated localisation of the
mitochondrial carrier protein homologue MCP6 from Trypanosoma brucei.
Eukaryotic Cell, 5:1194-1205.
Alibu VP, Richer C, Voncken F, Marti G, Shahi S, Renggli CK, Seebeck T,
Brun R, and Clayton C. (2006): The Role of Trypanosoma brucei MRPA in
melarsoprol susceptibility. Mol Biochem Parasitol.146 (1): 38-44.
Alibu VP Storm L, Haile S, Clayton C and Horn D. (2005): A doubly inducible
system for RNA interference and Rapid RNAi plasmid construction in
Trypanosoma brucei. Mol Biochem Parasitol. 139 (1): 75-82.
Alibu VP and Egwang TG (2003). Genomics Research and Malaria Control:
Great Expectations. PloS Biology. 1 (2): 142 – 144.
Clayton C, Horn D, Estevez A, Hartmann C, Alibu VP and Field M. (2005):
Down – Regulating gene expression by RNA interference in Trypanosoma
brucei. Methods in Molecular Biology. Vol. 309:39-60 (Ed. Gordon
Carmichael, Humana Press).
Research Funding:
I.
II.
III.
IV.
Co-PI TrypanoGEN+, funded by The Wellcome Trust (UK) GBP 2500,000.00, as part
of the H3Africa Consortium looking at the genetic determinants for susceptibility to
Human African trypanosomiasis and schistosomiasis (Oct 2018 –Sept 2021)
Afrique One Postdoctoral Fellowship (Wellcome Trust funded) GBP 150,000 (January
2011 - December 2014)
Co-PI: TrypanoGEN: An integrated approach to the identification of genetic
determinants of susceptibility to trypanosomiasis. This is a network funded by The
Welcome Trust, GBP 2,650,000.00 (April 2013 to March 2018) under H3Africa
Consortium. Here I am a member of the Bioethics and Governance Working Group
where I actively participate in policy document development, including guidelines for
community engagement (CE) (April 2013- March 2018).
Co-PI: Development and Application of Xenomonitoring tool in Human African
trypanosomiasis control Programs in endemic countries. This is funded by The Bill
and Melinda Gates Foundation (USD 8,000,000.00). (2008-2013)
Postgraduate students supervised:
1.
2.
3.
4.
5.
6.
Charles Kato Drago, PhD Biology (MUK), graduated 2016
Samuel Erechu, MSc Molecular Biology (MUK), graduated, 2016
Ambrose Mukisa, MSc Biochemistry (MUK), graduated 2016
Diana Katiti, MSc Molecular Biology (MUK), graduated 2015
Alex Boobo, MSc Molecular biology (MUK), graduated 2015
Prossy Namuwulya, MSc Molecular Biology (MUK), graduated 2014.
3